Tang Yuewu, Luo Yi
Department of Nephrology, Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, China.
Department of Blood Transfusion, Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, China.
Arch Rheumatol. 2022 Sep 20;37(4):566-573. doi: 10.46497/ArchRheumatol.2022.9167. eCollection 2022 Dec.
This study aims to analyze the relationship between complement receptor 2 (CR2) gene mutation and the clinical phenotype in Chinese familial systemic lupus erythematosus (SLE).
A total of one Chinese familial SLE patients (median age: 30.25 years; range, 22 to 49 years) were included between January 2017 and December 2018. The clinical features and diagnoses of familial SLE patients were analyzed using whole-exome sequencing (WES) of genomic deoxyribonucleic acid (DNA) samples. Sanger sequencing was used to verify candidate mutations detected in the examined family.
The mother and her three daughters were diagnosed with SLE. The clinical characteristics showed that the patient and her mother were diagnosed with lupus nephritis. The eldest daughter had decreased renal function and lower serum albumin levels. Immunological index analysis showed that all four patients were positive for anti-SSA and antinuclear antibody (ANA), but that only the second daughter was positive for anti-double-stranded DNA (dsDNA). Complement 3 (C3) was significantly decreased in all patients, while evaluation of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) showed that the second and third daughters had mild active SLE. The mother and eldest daughter were treated with prednisolone combined with cyclophosphamide, while the other two daughters were treated with prednisolone alone. The WES and Sanger sequencing analyses revealed an unreported missense T>C mutation c.2804 in the 15 exon of the CR gene in all four patients.
We identified a novel c.2804 (exon 15) T>C mutation in the CR gene of Chinese familial SLE. This mutation was previously reported, suggesting that the CR gene c.2804 (exon 15) T>C mutation is the probable cause of SLE in this family.
本研究旨在分析中国家族性系统性红斑狼疮(SLE)中补体受体2(CR2)基因突变与临床表型之间的关系。
2017年1月至2018年12月期间共纳入1例中国家族性SLE患者(中位年龄:30.25岁;范围22至49岁)。使用基因组脱氧核糖核酸(DNA)样本的全外显子组测序(WES)分析家族性SLE患者的临床特征和诊断。采用桑格测序法验证在受检家族中检测到的候选突变。
母亲及其三个女儿被诊断为SLE。临床特征显示,患者及其母亲被诊断为狼疮性肾炎。大女儿肾功能下降且血清白蛋白水平较低。免疫指标分析显示,所有4例患者抗SSA和抗核抗体(ANA)均为阳性,但只有二女儿抗双链DNA(dsDNA)呈阳性。所有患者的补体3(C3)均显著降低,而系统性红斑狼疮疾病活动指数(SLEDAI)评估显示二女儿和三女儿患有轻度活动性SLE。母亲和大女儿接受泼尼松龙联合环磷酰胺治疗,而另外两个女儿仅接受泼尼松龙治疗。WES和桑格测序分析显示,所有4例患者的CR基因第15外显子存在未报道的错义T>C突变c.2804。
我们在中国家族性SLE的CR基因中鉴定出一种新的c.2804(第15外显子)T>C突变。此前曾报道过这种突变,提示CR基因c.2804(第15外显子)T>C突变可能是该家族SLE的病因。